Faden Lab

We look forward to the event, and are proud to be a sponsor!

Looking forward to this summit @broadinstitute - great speaker lineup!

Grateful to our sponsors — @NateraOncology , @Naveris_inc @NeoGenomics @DropletBiosci and Adela @MGBResearchNews

At a time of rapid progress in liquid biopsy, the summit will offer an important opportunity to connect across disciplines, exchange ideas, and discuss the future of cancer detection, monitoring, and clinical care. G

Thrilled to host the inaugural Head and Neck Cancer Liquid Biopsy Summit July 17th, 2026, @broadinstitute in Cambridge MA See the outstanding speaker lineup on the meeting website: eventleaf.com/e/HeadandNeckC… Registration is free and open to all Additional details 👇👇👇

And last but not least, I was truly surprised (and touched) by the cake and champagne celebrating my recent promotion to Associate Professor at Harvard Medical School. It’s an honor to work with, teach, and learn from such remarkable people. @MGBResearchNews @MassGenBrigham

I’m also deeply thankful for an outstanding lab and collaborators here in Boston—who led a terrific journal club last night on emerging ctDNA trials, co-hosted with Viktor Adalsteinsson and his team @broadinstitute.

Feeling especially grateful today for the opportunities that have shaped my early career. Training at @UCSF_OHNS was an incredible experience and gave me the foundation to grow as a surgeon-scientist.

Human papilloma virus (HPV) causes around 70% of head and neck cancers in the United States, making it the most common cancer caused by the virus, with rates increasing each year. Unlike cervical cancers caused by HPV, there is no screening test for HPV-associated head and neck cancers. This means that patients are usually diagnosed after a tumor has grown to billions of cells in size, causing symptoms and spreading to lymph nodes. Screening methods that can detect these cancers much earlier could mean treatment interventions for patients sooner. In a new study, Mass General Brigham researchers show that a novel liquid biopsy tool they developed, called HPV-DeepSeek, can identify HPV-associated head and neck cancer up to 10 years before symptoms appear. By catching cancers earlier with this novel test, patients may experience higher treatment success and require a less intense regimen, according to the authors. spklr.io/6014DwOLC

2026 lab photo — hard to believe how far we’ve come in six years, growing from a lab of one into the team we are today. Proud of the impactful work this group continues to produce, but equally proud of the culture of collaboration.

Privileged to participate in the @SU2C summit on oropharynx and anal cancer early detection. Great exchange of ideas and hopeful for the advancements to come.

Despite all the challenges right now, nothing makes me prouder than learning that while I was in Germany presenting our lab’s work, the lab got together on their own to celebrate birthdays and personal milestones. Grants, papers, and keynotes are great—but this is what it’s about

In patients with locally advanced #HNSCC, ctDNA-based minimal residual disease positivity after treatment completion was associated with higher recurrence and worse survival, supporting its use as a prognostic biomarker. ja.ma/4b7i2M3

academic.oup.com/jnci/advance-a… academic.oup.com/jnci/advance-a…

Thank you to @DavidRoutmanMD and @aadel_chaudhuri for the beautifully written commentary in @JNCI_Now summarizing our recent HPV-DeepSeek manuscript demonstrating that HPV+ oropharynx cancer can be detected in the blood years before clinical diagnosis. Link to both articles below

academic.oup.com/jnci/advance-a… academic.oup.com/jnci/advance-a…

Tonight’s episode of @60Minutes will include a segment on the impact of federally funded science and recent cuts to science funding. Our lab’s development of base editing and prime editing and their clinical applications will be among the work described in the episode. paramountpressexpress.com/cbs-news-and-s…